Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Susan Tramazzo

Nurse Practitioner Jacksonville, FL Nurse Practitioner

NPI 1366750713 CMS profile 10811919

3101 University Blvd S Ste 102, Ste 102, Jacksonville, FL 32216

Open in the dashboard

General payments

$3,733

211 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Susan Tramazzo of Jacksonville, FL is reported in the CMS Open Payments database as having received $3,733 across 211 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $61 3
2024 General $54 3
2023 General $1,438 72
2022 General $1,464 90
2021 General $717 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Susan Tramazzo
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Susan Tramazzo were reported at $61. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Susan Tramazzo Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $717 $135 $40–$426 $132
2022 $1,464 $152 $48–$470 $149
2023 $1,438 $166 $54–$529 $160
2024 $54 $173 $55–$556 $164
2025 $61 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. GlaxoSmithKline, LLC. $381 20 payments
  2. Pfizer Inc. $342 22 payments
  3. Abbott Laboratories $339 14 payments
  4. AbbVie, Inc. $339 26 payments
  5. Novo Nordisk Inc $297 18 payments
  6. Lilly USA, LLC $251 16 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $251 14 payments
  8. AstraZeneca Pharmaceuticals LP $189 13 payments
  9. Sanofi-Aventis U.S. LLC $147 7 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $136 5 payments
  11. Other $1,061 56 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,648 210 payments
  2. Education $85 1 payment
Products named General payments · program years 2021–2025
  1. FreeStyle Libre 2 $250 7 payments
  2. ELIQUIS $226 14 payments
  3. Ozempic $220 13 payments
  4. RYBELSUS $220 13 payments
  5. TRELEGY ELLIPTA $184 11 payments
  6. JARDIANCE $168 10 payments
  7. MOUNJARO $144 9 payments
  8. UBRELVY $142 8 payments
  9. TRINTELLIX $136 5 payments
  10. NURTEC ODT $130 8 payments
  11. Other $3,020 196 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

308

Median for Nurse Practitioner: 389

Drug cost

$3,457

Median for Nurse Practitioner: $21,885

Branded share of claims

7.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 21 $815
Atorvastatin Calcium Generic 45 $368
Omeprazole Generic 14 $291
Bupropion Xl Bupropion Hcl Brand 12 $211
Rosuvastatin Calcium Generic 11 $210
Valsartan Generic 11 $205
Levothyroxine Sodium Generic 30 $202
Clonazepam Generic 14 $185
Tamsulosin Hcl Generic 12 $163
Lisinopril Generic 21 $134

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $9
$9 — —
QULIPTA
  • AbbVie, Inc. $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

211 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record